Rapamycin is an FDA-approved anti-cancer agent and immunosuppressant. Some research suggests it can even combat aging. But rapamycin also targets and inhibits the workings of two related molecular complexes in the liver, with potentially important effects on metabolism. In a study published online recently in The FASEB Journal, a team led by Dr. Philip Gruppuso, professor of pediatrics at Brown and Rhode Island Hospital, looked at what “mTORC2” — the less studied of the two complexes — does in the liver.
Read the story